Cargando…
Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review)
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer. According to the American Cancer Society, among patients diagnosed with advanced liver cancer, HCC has the sixth-highest incident rate, resulting in a poor prognosis. Surgery, radiofrequency ablation, transcatheter ar...
Autores principales: | Cheng, Mo, Zheng, Xiufeng, Wei, Jing, Liu, Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665984/ https://www.ncbi.nlm.nih.gov/pubmed/38023367 http://dx.doi.org/10.3892/etm.2023.12285 |
Ejemplares similares
-
Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art
por: Laschtowitz, Alena, et al.
Publicado: (2023) -
Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
por: Gok Yavuz, Betul, et al.
Publicado: (2021) -
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
por: Zhong, Cheng, et al.
Publicado: (2021) -
Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021) -
Immunotherapy for hepatocellular carcinoma: Current and future
por: Johnston, Michael P, et al.
Publicado: (2019)